Expertise
-
Practice Areas:
- Bar Admissions:
- Education:
- Osgoode Hall Law School (2016) JD
- University of Toronto (2013) PhD (Chemistry)
- Memorial University of Newfoundland (2008) BSc (Chemistry)
Details
- Bio
- Cases
- Associations
- Blog Posts
- News & Media
- Publications & Presentations
- Recognition
Corey McClary (he/him)
is counsel at Lenczner Slaght.
Corey's practice is primarily focused on intellectual property law, with an emphasis on pharmaceutical patent litigation. Corey has experience advising clients on complex disputes, including actions under the Patented Medicines (Notice of Compliance) Regulations, patent infringement and impeachment actions, and judicial review proceedings. Corey also regularly provides strategic patent and regulatory advice.
Prior to joining Lenczner Slaght, Corey summered, articled and practiced in the intellectual property litigation group at a leading international law firm in Toronto.
Before attending law school, Corey obtained a Ph.D. in organic chemistry. His graduate research focused on developing methods for the regioselective functionalization of carbohydrates and measuring the strength of non-covalent interactions. His research has been published in peer-reviewed scientific journals.
-
Genentech Inc and Hoffmann-La Roche Limited v Biosimilar Collaborations Ireland Limited
Counsel to Genentech Inc and Hoffmann-La Roche Limited in a PM(NOC) action in the Federal Court in respect of Canadian Patent Nos. 2,788,253 and 2,711,798.
-
Counsel to Hoffmann-La Roche Limited in an application for judicial review in the Federal Court, in respect of a decision made by the Minister of Health and its continued course of conduct in respect of the filing of a new drug submission by Biosimilar Collaborations Ireland Limited.
-
The NOCO Company, Inc. v Canadian Tire Corporation, Limited
Counsel to Canadian Tire Corporation, Limited in an action for patent infringement in the Federal Court in respect of Canadian Patent No. 2,916,782.
-
Merck Canada Inc v The Minister of Health
Counsel to Merck Canada Inc. in a judicial review proceeding in the Federal Court regarding an application for a certificate of supplementary protection for Canadian Patent No. 2,670,892 and BELSOMRA.
-
Gilead Sciences, Inc et al v Pharmascience Inc
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
-
Bernard Charles Sherman v Pfizer Canada Inc
Counsel to Pfizer Canada Inc. and Pfizer Inc. in an action for patent infringement in the Federal Court in respect of Canadian Patent No. 2,355,347.
-
Akebia Therapeutics Inc v Fibrogen Inc
Counsel to FibroGen Inc. and AstraZeneca AB in an impeachment action in the Federal Court in respect of Canadian Patent Nos. 2,468,083, 2,467,689, and 2,526,496.
-
Gilead Sciences, Inc et al v JAMP Pharma Corporation
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,990,210.
-
Gilead Sciences, Inc et al v Natco Pharma (Canada) Inc
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
-
Merck Canada Inc v The Minister of Health
Counsel to Merck Canada Inc. in a judicial review proceeding in the Federal Court in regards to a patent listing for KEYTRUDA.
-
Toronto Intellectual Property Group
-
Ontario Bar Association
-
Intellectual Property Institute of Canada - Patent Committee (2025-2027)
-
Health Canada’s Ministerial Reliance Order: A New Era in Canadian Drug Regulation
Health Canada has introduced a new Ministerial Reliance Order (MRO) that represents a significant development in Canada’s drug regulatory framework. The MRO creates a new mechanism allowing Health Canada, in defined circumstances, to rely on decisions or documents produced by comparable foreign regulatory authorities (FRAs) when reviewing certain drug submissions. The initiative aims to improve the efficiency of regulatory review while maintaining Canada’s standards for safety, efficacy, and quality.
-
A Tale of Two Standards: Why Hikma May Have Had a Different Fate in Canada
On June 4, 2026, the US Supreme Court issued its decision in Hikma Pharmaceuticals USA Inc v Amarin Pharma Inc, a motion to dismiss against the backdrop of a claim for inducement of patent infringement in the pharmaceutical context. The Court held that the patentee, Amarin, had not pleaded more than a “sheer possibility” that Hikma actively induced infringement under the applicable US plausibility standard. Would a Canadian court have reached the same conclusion on identical facts? Possible, but not “plausible.”
-
Fall Regulatory Round Up – The Shifting Shape of the Canadian Landscape
Fall Regulatory Round Up
Activity abounds on the regulatory landscape from modernization and transparency initiatives to consultations, collaborations, and even potential implementations. Our Fall Regulatory Round Up highlights significant developments for drug products and patents that are of interest to those in the life sciences and biotech spaces. We will be following these important regulatory initiatives as they continue to unfold and will provide updates of interest.
-
Lenczner Slaght Litigators Featured Among Best Lawyers in Canada
The 2026 edition of Best Lawyers in Canada recognizes Lenczner Slaght with 180+ rankings, featuring 48 of our expert litigators across 27 practice areas.
-
Lenczner Slaght Litigators Recognized as the Best Lawyers in Canada
In the 2025 edition of Best Lawyers in Canada, Lenczner Slaght is proud to receive 168 total rankings, with 45 of our expert litigators recognized for their expertise across 25 practice areas.
-
Corey McClary Joins Lenczner Slaght’s IP Team
Canada’s leading litigation firm continues to grow its expert Intellectual Property Group with the addition of another exceptional lawyer, Corey McClary.
-
The 18th Annual Harold G. Fox IP Moot
Sana Halwani and Corey McClary served as judges at the annual Harold G. Fox IP Moot.
-
2025 Snapshot: Through the Lens of Lenczner Slaght
We’ve released our 2025 Snapshot, highlighting the most significant developments, decisions, and trends in litigation from the past year across 21 practice areas. Reflect on 2025 and look ahead to 2026 through the lens of our expert litigators.
-
Corey McClary co-authored the article Organoboron-Promoted Regioselective Glycosylations in the Synthesis of a Saponin-Derived Pentasaccharide from Spergularia ramosa, published in The Journal of Organic Chemistry.
-
Corey McClary co-authored the article Applications of Organoboron Compounds in Carbohydrate Chemistry and Glycobiology: Analysis, Separation, Protection and Activation, published in Carbohydrate Research.
-
Corey McClary co-authored the article Anion Receptors Composed of Hydrogen- and Halogen-Bond Donor Groups: Modulating Selectivity With Combinations of Distinct Noncovalent Interactions, published in the Journal of the American Chemical Society.
-
Corey McClary co-authored the article Ligand Directed Self-Assembly vs. Metal Ion Coordination Algorithm - When Does the Ligand or the Metal Take Control?, published in Dalton Transactions.
-
Best Lawyers in Canada (2025-2026)
Ones to Watch – Intellectual Property